Yesterday, Alector hosted an R&D webinar on our Alector Brain Carrier (ABC) blood-brain barrier platform and highlighted our emerging therapies for degenerative brain disorders, including AL137, our next-generation anti-Aβ antibody, and our siRNA programs targeting tau and α-synuclein. Watch the replay here: https://lnkd.in/gbR7Y7GR
Alector
Biotechnology Research
South San Francisco, California 21,438 followers
We are on a mission to make brain disorders history.
About us
We are a late-stage clinical biotechnology company with a mission to make degenerative brain disorders history. Our robust portfolio of therapies is focused on counteracting the devastating progression of neurodegenerative diseases, particularly in areas of high unmet need where therapeutic options are limited. We are at the forefront of a scientific and clinical revolution, committed to understanding the complex mechanisms that drive neurodegenerative diseases, including the roles of toxic misfolded proteins, deficient proteins, and lysosomal, immune system, and neuronal dysfunction. We aim to develop product candidates that remove toxic proteins, replace critical deficient proteins, and restore immune and nerve cells to normal function. To pursue this aim, we are advancing a portfolio of programs that address genetically validated targets. These programs leverage our deep understanding of the genetic underpinnings of these diseases, combined with our expertise in drug development, proprietary protein engineering, antibody discovery, and our innovative Alector Brain Carrier (ABC) technology for blood-brain barrier (BBB) transport. We are advancing ABC, our proprietary, versatile BBB technology platform and selectively applying it within our portfolio. Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.
- Website
-
http://alector.com
External link for Alector
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2013
- Specialties
- Biotechnology, Neurodegenerative disease, and Neurodegeneration
Locations
-
Primary
Get directions
131 Oyster Point Blvd
Suite 600
South San Francisco, California 94080, US
Employees at Alector
Updates
-
Today is #WorldMentalHealthDay, a reminder that mental health is health — and that no one should face it alone. At Alector, we see every day how deeply brain health and emotional well-being are connected. We're committed to fostering a culture where our colleagues feel supported and breaking the stigma that keeps too many people from seeking care. Take a moment today to check in on yourself and on those around you. #MentalHealthAwareness #BrainHealth
-
-
Alector has entered into a global license agreement with Genentech, a member of the Roche Group, for AL050, our brain-penetrant GCase enzyme replacement therapy for Parkinson's disease. "Deficient GCase activity is increasingly recognized as a contributor to Parkinson's Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "Genentech's long-standing commitment to Parkinson's Disease makes them an ideal partner as this program moves toward the clinic." Read more: https://bit.ly/46WBBDx
-
-
On this #AlzheimersAwarenessDay, we stand alongside the millions of individuals, families, and caregivers impacted by Alzheimer’s disease. We remain committed to forging a future where neurodegenerative diseases no longer take away memories, independence, or meaningful connection. Our work, from research through development, is inspired by the strength of patients, the compassion of caregivers, and the perseverance of communities facing Alzheimer’s every day. To everyone navigating this journey: we see your strength, we honor your experiences, and we remain dedicated to driving meaningful progress
-
-
Our team is looking forward to participating in the upcoming September healthcare conferences in New York City. We hope to see you there! Cantor Fitzgerald, Morgan Stanley Read more here: https://lnkd.in/gPgeWqX4
-
-
Today, we reported second quarter 2026 financial results and recent portfolio and business updates. Read the full release: https://bit.ly/4gfj3Um #investors #biotech
-
-
Members of Alector management look forward to participating in the BTIG Virtual Biotechnology Conference on July 29! We are thrilled for the chance to discuss our ongoing, exciting work in the #neurodegenerative disease space and to reconnect with the #biotech community.
-
-
Did you know June is both #AlzheimersAwarenessMonth and #BrainAwarenessMonth? At Alector, we join the global community in honoring the strength of those impacted by neurodegenerative diseases and the researchers working tirelessly to bring hope to patients and families. We recognize the importance of raising awareness about brain science and its role in supporting healthier lives. Learn more about our dedication to advancing work in #neurodegenerativediseases: http://bit.ly/3IA6AfQ
-
-
Happy #PrideMonth! At Alector, we celebrate the importance of creating a community where everyone feels safe, supported, and empowered to live as their authentic self.
-